Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I/II data show VIR-576 to be safe and effective in HIV

Nov. 16, 2009

BMS-650032 shows potent anti-HCV activity in two phase II trials

Nov. 16, 2009

ITMN-191 monotherapy for HCV infection correlates with high barrier to viral escape

Nov. 16, 2009

AST-120 improves pruritus in patients with chronic liver disease

Nov. 16, 2009

Analyses of phase III data detail activity of fidaxomicin against C. difficile infection

Nov. 16, 2009

HIV infection therapeutic TBR-652 shows good PK and safety profile in healthy subjects

Nov. 13, 2009

INX-189 exhibits anti-HCV activity in vitro and extensive liver delivery in vivo

Nov. 13, 2009

TMC-435 retreatment successful in HCV patients

Nov. 13, 2009

Phase III H5N1 vaccine safe and strongly immunogenic

Nov. 13, 2009

ErbB4 gene variation linked to paliperidone response in schizophrenia patients

Nov. 13, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...